ADCT | NYSE

Adc Therapeutics Sa

Adc Therapeutics Sa (ADCT) | runway 18.3 months | financing risk moderate | market cap $479.5M. Daily snapshot of financials, capital pressure, and recent de...

Company websiteLast updated Apr 29, 2026

Share price

$3.78

As of Apr 29, 2026

Market cap

$479.5M

Snapshot valuation

30D volume

898,551 shares

Rolling average daily volume

Runway

18.3 months

Estimated from precomputed burn and cash

Financing risk

N/A

Financing risk is present, but the current picture is not yet acute.

Snapshot summary

Runway: 18.3 months based on estimated burn.

Financing signal: Financing risk is present, but the current picture is not yet acute.

Latest development: ADC Therapeutics SA 424B3 2026-04-15.

Recent developments

ADC Therapeutics SA 424B3 2026-04-15

424B3 filing submitted on 2026-04-15.

Apr 14, 2026, 8:00 PM

ADC Therapeutics SA 424B3 2026-03-16

424B3 filing submitted on 2026-03-16.

Mar 15, 2026, 8:00 PM

ADC Therapeutics SA S-3 2026-03-10

S-3 filing submitted on 2026-03-10.

Mar 9, 2026, 8:00 PM

ADC Therapeutics SA 10-K 2026-03-10

10-K filed on 2026-03-10.

Mar 9, 2026, 8:00 PM

ADC Therapeutics SA 8-K 2026-03-10

8-K filed on 2026-03-10.

Mar 9, 2026, 8:00 PM

Premium analysis

Full filing analysis and proprietary signal detail

Detailed impact scoring, historical financial trends, full filing analysis, premium alerts, and proprietary signal explanations stay behind login and subscription.

Full filing analysis with event-level impact scoring
Historical financial trends and runway context
Detailed signal breakdowns and proprietary explanations
Premium alerts, filters, and watchlist workflows
Deeper financing and dilution analysis
Timeline context across filings and disclosures